Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

INTRODUCTION: Alzheimer’s disease (AD) is a progressive, neurodegenerative disease and is the most common cause of dementia. Lecanemab is a humanized monoclonal antibody targeting amyloid protofibrils for the treatment of early AD. In the phase II BAN2401-G000-201 trial (NCT01767311), lecanemab redu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahami Monfared, Amir Abbas, Tafazzoli, Ali, Ye, Weicheng, Chavan, Ameya, Zhang, Quanwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095799/
https://www.ncbi.nlm.nih.gov/pubmed/35469060
http://dx.doi.org/10.1007/s40120-022-00350-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095799/
https://www.ncbi.nlm.nih.gov/pubmed/35469060
http://dx.doi.org/10.1007/s40120-022-00350-y

Ejemplares similares